Brian Buntz is a Pharma Editor with a focus on the pharmaceutical industry. He writes for publications such as Drug Discovery & Development and Medical Design Sourcing, covering topics ranging from medication promotion to future-readiness rankings in the pharma sector. His work has also been featured in Medical Design & Outsourcing, TED Conferences, and MassDevice.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
Brian Buntz's articles primarily focus on the healthcare and pharmaceutical industry, with a strong emphasis on data-driven insights. His coverage suggests an interest in topics such as pharmaceutical innovation, M&A activity, emerging trends in drug approvals, and AI applications within healthcare.
Given his reliance on citing data and press releases, Brian may be interested in pitches that provide comprehensive data analysis or newsworthy findings related to pharmaceuticals, medical research advancements, or trends in healthcare technology. Additionally, he might be open to receiving press releases announcing significant developments within the healthcare and pharmaceutical sectors.
While Brian's geographic focus is not specified, his coverage appears to encompass global perspectives on the healthcare and pharmaceutical industry. Therefore, relevant pitches should consider international implications or broader industry trends rather than focusing solely on specific regional matters unless they have global significance.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The global automation firm Emerson (NYSE: EMR) had announced a major update to its Ovation automation platform. Ovation 4.0 introduces a software-defined architecture designed to empower utilities in the power and water industries to tap data, new technologies, and artificial intelligence (AI) for enhanced operational excellence, reliability, affordability, and sustainability.
R&D is the primary driver of countries’ growth.
By: Brian Buntz
| In some ways, machine learning is nothing new. The term itself dates back to 1958 when the computer scientist Arthur Lee Samuel coined
By: Brian Buntz
| Small-molecule drugs have been a mainstay of medicine for over a century, including many of the most impactful pharmaceuticals in human history, such as aspirin and penicillin.
By: Brian Buntz
Crafting comprehensive articles from scratch can be a tedious process. But what if AI could lend a hand — at least in writing summary articles of well-defined research topics?
By: Brian Buntz
LinkedInEmailShare Imagine a world without rockets. No satellites beaming down GPS signals, no astronauts exploring the cosmos, no spellbinding images of distant galaxies. But for most of human history, the idea of escaping Earth’s gravity was just a distant dream.
By: Brian Buntz
LinkedInEmailShare Forget writer’s block — Insilico Medicine’s new AI tool, DORA, unleashes an “army of [AI] agents” to churn out a scientific research paper draft in about 20 minutes.
By: Brian Buntz
Insilico Medicine's DORA aims to accelerate scientific writing in drug discovery and beyond. As a journalist, I gave it a test drive.
By: Brian Buntz
Why are rockhounds exploring the shores of Lake Superior after dark, armed with UV flashlights? The answer lies in the glow of Yooperlites.
R&D salary trends 2024: Analysis of 1,530 job listings reveals competitive pay scales across various industries
(833) 317-6278 
